Clinical Trials Logo

Clinical Trial Summary

Background Somatostatin and octreotide LAR (long-acting analogue) exert a number of inhibitory effects: on gut hormones, but also on gastro-intestinal secretion and motility.

Somatostatin analogues are effective in preventing symptoms and signs of both early and late dumping as demonstrated previously. However, octreotide LAR causes gastrointestinal side effects and the injection solution is difficult to prepare. Recently, a new somatostatin analogue with a prolonged release formulation, Lanreotide autogel (L-autogel), has become available. It is a viscous aqueous gel, composed solely of water and lanreotide. Deep subcutaneous administration may lead to increased treatment acceptance compared with intramuscular depot preparations. It is more easy to prepare and is though to cause less local side effects and technical problems than octreotide LAR. Recent studies have been done to measure the efficacy and safety of L-autogel in acromegalic treated previously with octreotide LAR. These studies showed that L-autogel is effective and well-tolerated in these patients, with equivalent or better disease control and less gastrointestinal adverse events. Until now, there is no data available on the effectivety of L-autogel in patients with a dumping syndrome. Therefore, this study aims to establish the effectiveness and tolerability of L-autogel in patients with a dumping syndrome, previously treated with octreotide LAR.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00543179
Study type Interventional
Source Radboud University
Contact Serena Slavenburg, MD
Phone +31243617272
Email s.slavenburg@mdl.umcn.nl
Status Recruiting
Phase Phase 4
Start date October 2007

See also
  Status Clinical Trial Phase
Recruiting NCT05759689 - Fat Supplementation on Dumping Syndrome Related Symptoms After Gastric Surgery N/A
Recruiting NCT04028193 - Fat Supplementation on Dumping Syndrome Associated Symptoms N/A
Not yet recruiting NCT04522193 - Dumping Syndrome and Esophageal Atresia N/A
Completed NCT02891330 - Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for Obesity N/A
Completed NCT02525705 - Dumping Syndrome After Operation of Esophageal Atresia Type III N/A
Active, not recruiting NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Phase 4
Completed NCT03734627 - Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
Terminated NCT02836353 - Metabolic Consequences of Gastrointestinal Surgery N/A
Completed NCT05057819 - Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass Phase 4
Completed NCT02971631 - Gastrectomy, Eating Behaviour and GLP-1 N/A
Completed NCT01923649 - SOMATULINE Autogel 90 mg IN DUMPING SYNDROME Phase 2